Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 436 to 450 of 1834 results for carers

  1. Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis

  2. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

  3. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  4. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

  5. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available...

  6. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

  7. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  8. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

  9. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.

  10. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

  11. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

  12. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

  13. Hyperphosphatemia in people with CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?

    CKD stage 4 or 5: What are people with CKD and their family members and carers views and beliefs about taking oral phosphate binders?...

  14. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence (CG76)

    This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.